161 related articles for article (PubMed ID: 18176661)
1. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders.
Rosenzweig-Lipson S; Dunlop J; Marquis KL
Drug News Perspect; 2007 Nov; 20(9):565-71. PubMed ID: 18176661
[TBL] [Abstract][Full Text] [Related]
2. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
3. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Prog Brain Res; 2008; 172():287-305. PubMed ID: 18772038
[TBL] [Abstract][Full Text] [Related]
4. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
Berg KA; Harvey JA; Spampinato U; Clarke WP
Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
[TBL] [Abstract][Full Text] [Related]
5. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
Bubar MJ; Cunningham KA
Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms.
Fentress HM; Grinde E; Mazurkiewicz JE; Backstrom JR; Herrick-Davis K; Sanders-Bush E
Pharmacogenomics J; 2005; 5(4):244-54. PubMed ID: 15912142
[TBL] [Abstract][Full Text] [Related]
7. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
8. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
9. 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice.
Somerville EM; Horwood JM; Lee MD; Kennett GA; Clifton PG
Eur J Neurosci; 2007 May; 25(10):3115-24. PubMed ID: 17561825
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.
Fletcher PJ; Tampakeras M; Sinyard J; Slassi A; Isaac M; Higgins GA
Neuropharmacology; 2009 Sep; 57(3):259-67. PubMed ID: 19501602
[TBL] [Abstract][Full Text] [Related]
11. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
Wacker DA; Miller KJ
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of 5HT(2C) receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing.
Werry TD; Stewart GD; Crouch MF; Watts A; Sexton PM; Christopoulos A
Biochem Pharmacol; 2008 Nov; 76(10):1276-87. PubMed ID: 18812172
[TBL] [Abstract][Full Text] [Related]
13. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.
Andrews MD; Green MP; Allerton CM; Batchelor DV; Blagg J; Brown AD; Gordon DW; McMurray G; Millns DJ; Nichols CL; Watson L
Bioorg Med Chem Lett; 2009 Sep; 19(18):5346-50. PubMed ID: 19692241
[TBL] [Abstract][Full Text] [Related]
15. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
16. Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
Chanrion B; Mannoury la Cour C; Gavarini S; Seimandi M; Vincent L; Pujol JF; Bockaert J; Marin P; Millan MJ
Mol Pharmacol; 2008 Mar; 73(3):748-57. PubMed ID: 18083778
[TBL] [Abstract][Full Text] [Related]
17. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling.
Berg KA; Dunlop J; Sanchez T; Silva M; Clarke WP
J Pharmacol Exp Ther; 2008 Mar; 324(3):1084-92. PubMed ID: 18065501
[TBL] [Abstract][Full Text] [Related]
18. Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.
Miller KJ
Mol Interv; 2005 Oct; 5(5):282-91. PubMed ID: 16249524
[TBL] [Abstract][Full Text] [Related]
19. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems.
Giorgetti M; Tecott LH
Eur J Pharmacol; 2004 Mar; 488(1-3):1-9. PubMed ID: 15044029
[TBL] [Abstract][Full Text] [Related]
20. Identification of 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT2C receptor agonists.
Röver S; Adams DR; Bénardeau A; Bentley JM; Bickerdike MJ; Bourson A; Cliffe IA; Coassolo P; Davidson JE; Dourish CT; Hebeisen P; Kennett GA; Knight AR; Malcolm CS; Mattei P; Misra A; Mizrahi J; Muller M; Porter RH; Richter H; Taylor S; Vickers SP
Bioorg Med Chem Lett; 2005 Aug; 15(15):3604-8. PubMed ID: 15975787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
